You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》加科思药业(01167.HK)公开发售超购逾298倍上限定价 一手中签率15%
阿思达克 12-18 08:57
临床阶段制药公司加科思药业(01167.HK)公布招股结果,发售价定於14元,为上限定价(招股价介乎每股12至14元),公开发售录超购298.59倍,经重新分配後,公开发售股数增至50%。每手300股,中签率为15%。该股将於下周一(21日)上市。高盛及中金为联席保荐人。

公司为上市引入6名基石投资者,包括LAV Funds、Matthews Funds、哈德逊湾资本、Octagon Investments等,合共认购3,322.08万股股份,占紧随全球发售完成後公司已发行股本的约4.37%。

公司预计集资所得款项净额约为12.63亿元,当中88%将主要用於产品的临床开发及商业化;8%将用於建造符合GMP标准的内部生产设施;余下4%将作为一般企业及营运资金用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account